EP3 Antagonists Preserve Pancreatic Beta-Cell Viability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes, particularly type 1 and type 2 diabetes, fail to effectively preserve pancreatic beta-cell viability and function, leading to progressive dysfunction and increased insulin resistance, with no cure available for type 1 diabetes and limited therapeutic options for both types.
Innovation Solution
Development of novel prostaglandin receptor 3 (EP3) antagonists that inhibit EP3-mediated signaling, specifically compounds represented by Formulae I, II, and III, which are capable of rescuing MIN6 and human islet beta cells from apoptosis and restoring glucose-stimulated insulin secretion, exhibiting enhanced efficacy and safety compared to existing EP3 antagonists.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional diabetes treatments are used, then blood glucose levels may be controlled, but pancreatic beta-cell viability and function deteriorate progressively
Solution Approach 1:
The patent applies preliminary anti-action by using EP3 antagonists to prevent apoptotic signaling pathways before beta-cell death occurs. The compounds block EP3-mediated signaling that leads to apoptosis, thereby preventing cell death rather than treating it after occurrence. This is evidenced by the disclosure that EP3 antagonists reduce apoptosis in pancreatic beta cells exposed to diabetogenic conditions.
Solution Approach 2:
The patent converts the harmful effect of EP3-mediated signaling into a beneficial outcome by using EP3 antagonists to block this pathway. The harmful apoptotic signaling through EP3 receptors is transformed into a protective effect where blocking EP3 prevents beta-cell death and preserves insulin secretion capacity, turning a detrimental pathway into a therapeutic opportunity.
2Reliability
If existing EP3 antagonists are used, then some protective effect is achieved, but therapeutic efficacy is insufficient compared to novel compounds
Solution Approach 1:
The patent applies parameter changes by optimizing the chemical structure of EP3 antagonists to achieve superior efficacy. The novel compounds represented by Formulae I, II, and III exhibit enhanced potency and selectivity compared to existing antagonists. This is demonstrated by the disclosure that these compounds show improved ability to preserve beta-cell mass and enhance glucose-stimulated insulin secretion, representing optimized pharmacological parameters.
3Quantity of substance
If beta-cell mass is maintained through current therapies, then insulin production is preserved, but insulin resistance and glycemic control worsen
Solution Approach 1:
The patent applies universality by demonstrating that EP3 antagonists achieve multiple therapeutic effects simultaneously. The compounds not only preserve beta-cell mass by reducing apoptosis but also enhance insulin secretion capacity and improve glycemic control. This multi-functionality is evidenced by the disclosure that EP3 antagonists address both beta-cell protection and functional improvement, providing comprehensive diabetes management.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The identified compounds significantly enhance pancreatic beta-cell viability and function, reducing apoptosis, increasing insulin secretion, and improving glycemic control, insulin resistance, and lipid profiles in diabetic models, offering improved therapeutic modalities for diabetes management.
Implementation Method 1
novel prostaglandin receptor 3 (EP3) antagonists that inhibit EP3-mediated signaling
Implementation Method 2
restoring glucose-stimulated insulin secretion
Data Source
AI summary
The present invention provides compositions and methods for preserving pancreatic β-cell populations and for the treatment of diabetes. In particular, embodiments of the invention relate to the use of newly identified prostaglandin receptor 3 (EP3) antagonists that are exceptionally effective in enhancing the viability and/or activity of pancreatic P cells.